Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aptose Biosciences Inc (OP:APTOF)

1.690 UNCHANGED
Last Price Updated: 11:53 AM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.690
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 1.690
Today's Range 1.690 - 1.690
52wk Range 1.189 - 1.742
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation
From Aptose Biosciences, Inc.
Via GlobeNewswire

Performance

52-Week Range 3.0% below 52-week high
1.690
1.1952W Low 1.7452W High

Aptose Biosciences Inc (APTOF) traded between $1.19 and $1.74 over the past 52 weeks and last traded at $1.69, 3.0% below its 52-week high.

Past 12 Months
N/A
N/A
N/A
-1.2%
+9.8%
+34.1%
1W  
1M  
3M  
6M -$0.02
YTD +$0.15
1Y +$0.43

APTOF was +34.1% over the past year, -1.2% over six months, +9.8% year to date.

12 Months vs Market
APTOF
+34.1%
DIA
+12.3%
SPY
+14.6%
QQQ
+17.3%
IWM
+11.1%

Over the past 12 months APTOF returned +34.1% versus DIA (Dow) +12.3%, SPY (S&P 500) +14.6%, QQQ (Nasdaq 100) +17.3% and IWM (Russell 2000) +11.1%.

Volume & Liquidity
6M
2.4K
YTD
5.6K
1Y
6.5K

More News

Read More
News headline image
Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Reports First Quarter 2026 Results
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Reports Third Quarter 2025 Results
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Reports Second Quarter 2025 Results
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Upgraded to Trade on OTCQB Market
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose Announces Deferral of Interest Payment
From Aptose Biosciences, Inc.
Via GlobeNewswire
News headline image
Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML
From Aptose Biosciences, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Aptose Biosciences Inc publicly traded?
Yes, Aptose Biosciences Inc is publicly traded.
What exchange does Aptose Biosciences Inc trade on?
Aptose Biosciences Inc trades on the OTC Traded
What is the ticker symbol for Aptose Biosciences Inc?
The ticker symbol for Aptose Biosciences Inc is APTOF on the OTC Traded
What is the current price of Aptose Biosciences Inc?
The current price of Aptose Biosciences Inc is 1.690
When was Aptose Biosciences Inc last traded?
The last trade of Aptose Biosciences Inc was at 07/02/26 11:53 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.